EC

Euclidean Capital

North America, New York, United States, New York

Description

Euclidean Capital is the private investment firm and family office for James Simons, the renowned mathematician and founder of the quantitative hedge fund Renaissance Technologies. Established to manage Simons' personal wealth, Euclidean Capital employs a sophisticated, long-term investment strategy across a diverse range of asset classes, including public equities, private equity, venture capital, and real estate. The firm is known for its patient capital and fundamental-driven approach, often seeking opportunities in areas that align with Simons' background in mathematics and science, such as deep technology, biotechnology, and data-intensive industries.

In the venture capital and private equity space, Euclidean Capital typically acts as a strategic investor, often participating in later-stage growth rounds rather than early seed or Series A stages. Their investments are characterized by a focus on companies with strong technological foundations and significant market potential. The firm's unique structure as a family office allows for greater flexibility in investment size and holding periods compared to traditional institutional funds, enabling them to support companies through multiple growth phases.

Euclidean Capital has built a notable portfolio of high-growth companies. For instance, they were an investor in Databricks' substantial $1.6 billion Series G funding round, demonstrating their capacity to participate in significant capital raises for leading technology firms. Similarly, their involvement in companies like Stripe and their early support for Moderna underscore their interest in transformative businesses. While specific "first cheque" sizes are not publicly disclosed, their participation in such large rounds suggests an ability to deploy substantial capital, with typical initial commitments often ranging from $10 million to over $100 million for strategic private investments.

The firm's investment philosophy reflects James Simons' analytical rigor and long-term vision, making Euclidean Capital a distinctive player in the investment landscape. They are less focused on rapid exits and more on fostering long-term value creation, leveraging their deep understanding of complex systems and data. This approach positions them as a valuable partner for companies seeking not just capital, but also strategic alignment with a highly sophisticated investor.

Investor Profile

Euclidean Capital has backed more than 52 startups, with 8 new investments in the last 12 months alone. The firm has led 4 rounds, about 8% of its total and boasts 5 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Sweden, India.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Led 1 rounds in the past year.
  • Typical check size: $10M – $100M.

Stage Focus

  • Series B (25%)
  • Series A (25%)
  • Series C (19%)
  • Series Unknown (13%)
  • Series E (8%)
  • Series F (4%)
  • Series D (4%)
  • Seed (2%)

Country Focus

  • United States (96%)
  • Sweden (2%)
  • India (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Artificial Intelligence (Ai)
  • Medical Device
  • Genetics
  • Life Science
  • Financial Services
  • Fintech
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Euclidean Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 4
Team8
Asia, Tel Aviv, Israel, Tel Aviv-yafo
Co-Investments: 5
Alexandria Venture Investments
North America, California, United States, Pasadena
Co-Investments: 8
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 4
Casdin Capital
North America, New York, United States, New York
Co-Investments: 5
Viking Global Investors
North America, Connecticut, United States, Stamford
Co-Investments: 4
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 6
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 5
The Column Group
North America, California, United States, San Francisco
Co-Investments: 18
Illumina Ventures
North America, California, United States, Foster City
Co-Investments: 4

Which angels does Euclidean Capital often collaborate with?

TW
North America, California, United States, San Francisco
Shared Deals: 1
JD
North America, California, United States, Menlo Park
Shared Deals: 2
Shai Wininger
Asia, Israel
Shared Deals: 1
JC
North America, California, United States, San Jose
Shared Deals: 2
JT
North America, Illinois, United States, Chicago
Shared Deals: 1
BG
North America, Washington, United States, Seattle
Shared Deals: 3
Dave Strohm
North America, California, United States, San Francisco
Shared Deals: 1
LP
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by Euclidean Capital?

april

New York, New York, United States

April offers embedded tax planning and filing tools that integrate into financial platforms to power smarter, real-time tax decisions.

Financial ServicesFinTechInformation TechnologyTax ConsultingTax Preparation
Series BJul 23, 2025
Amount Raised: $38,000,000
Savvy Wealth

New York, New York, United States

Savvy Wealth is a technology-enabled wealth management firm that provides a digital-first platform for financial advisors.

Financial ServicesFinTechInformation TechnologyPersonal FinanceWealth Management
Series BJul 2, 2025
Amount Raised: $72,000,000
Actio Biosciences

San Diego, California, United States

Actio Biosciences is a research center that develops drugs for rare diseases.

BioinformaticsBiotechnologyGenetics
Series BJun 18, 2025
Amount Raised: $66,000,000
Neurona Therapeutics

San Francisco, California, United States

Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.

BiotechnologyHealth CareTherapeutics
Series FApr 3, 2025
Amount Raised: $102,000,000
Zeitview

Los Angeles, California, United States

Zeitview is an aerial data analytics platform that provides aerial drone services for energy and infrastructure sectors.

Artificial Intelligence (AI)ConstructionDronesMapping Services
Series UnknownMar 5, 2025
Amount Raised: $60,000,000
Leal Therapeutics

Worcester, Massachusetts, United States

Leal Therapeutics develops novel therapeutics for patients.

MedicalTherapeutics
Series UnknownOct 30, 2024
Amount Raised: $6,000,000
Judo Bio

Cambridge, Massachusetts, United States

Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.

BiotechnologyLife ScienceMedicalTherapeutics
Series AOct 7, 2024
Amount Raised: $75,000,000
Nura Bio

South San Francisco, California, United States

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases.

BiotechnologyHealth CareMedicalWellness
Series ASep 17, 2024
Amount Raised: $68,000,000
Circle Pharma

San Francisco, California, United States

Circle Pharma is a biotechnology company creating bioavailable macrocyclic peptide therapeutics that target protein-protein interactions.

BiotechnologyClinical TrialsHealth CareTherapeutics
Series DSep 3, 2024
Amount Raised: $90,000,000
Neo Asset Management

Mumbai, Maharashtra, India

Neo Asset Management offers portfolio management, investment advisory services, and asset allocation strategies to their clients.

Asset ManagementConsultingFinanceFinancial Services
Series UnknownAug 12, 2024
Amount Raised: $47,642,582